
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.03 | 7.13049498096 | 14.445 | 16.28 | 13.27 | 1382654 | 14.82942944 | CS |
4 | 0.086 | 0.558840730392 | 15.389 | 16.465 | 13.22 | 1129421 | 14.83535418 | CS |
12 | 0.585 | 3.92881128274 | 14.89 | 16.465 | 12.25 | 1029009 | 14.26824813 | CS |
26 | 11.135 | 256.566820276 | 4.34 | 23.4 | 3.98 | 2247746 | 14.47203411 | CS |
52 | 10.735 | 226.476793249 | 4.74 | 23.4 | 3.52 | 1300726 | 13.05252471 | CS |
156 | 10.975 | 243.888888889 | 4.5 | 23.4 | 2.68 | 540621 | 11.31987356 | CS |
260 | 14.325 | 1245.65217391 | 1.15 | 23.4 | 0.88 | 948367 | 7.92831089 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales